Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › pimavanserin

pimavanserin

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of pimavanserin

14 trials tracked of pimavanserin: 9 in phase 3 or 4 and 4 with published results. The most-cited published study has 13 citations.

14Trials tracked
9Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 2 Phase 3 7 Phase 2 5
  1. Phase 3 A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease Completed · 13 cited
  2. Phase 3 Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia Completed · 6 cited
  3. Phase 4 Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis Completed · 4 cited
  4. Phase 3 Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1) Completed · 3 cited
  5. Phase 4 Pimavanserin for Insomnia In Veterans With Posttraumatic Stress Disorder Completed
  6. Phase 3 Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment Completed
Show 8 more trials
  1. Phase 3 Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease Completed
  2. Phase 3 Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder Completed
  3. Phase 3 A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis Completed
  4. Phase 2 A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease Completed
  5. Phase 2 Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY) Completed
  6. Phase 2 A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis Completed
  7. Phase 2 Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE) Completed
  8. Phase 2 Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression Completed

Showing the 14 most-cited and recently-updated of 14 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Pimavanserin adjunctive therapy shows small statistically significant reductions in PANSS scores below clinically meaningful thresholds for schizophrenia
Psychiatry Meta-analysis
Pimavanserin adjunctive therapy shows small statistically significant reductions in PANSS scores below clinically meaningful thresholds for schizophrenia Review finds pimavanserin offers little for schizophrenia negative symptoms
This systematic review and meta-analysis evaluated adjunctive pimavanserin in 1676 randomized participants with schizophrenia. The analysis …
A major review of 1,676 adults with schizophrenia found adding pimavanserin did not meaningfully improve negative symptoms, despite small st…
Jun 1, 2026
FDA Approves Nuplazid (pimavanserin) for Parkinson's Disease Psychosis
Neurology FDA Approval
FDA Approves Nuplazid (pimavanserin) for Parkinson's Disease Psychosis FDA approves first drug for hallucinations in Parkinson's disease
The FDA approved Nuplazid (pimavanserin) for hallucinations and delusions associated with Parkinson's disease psychosis. Approval was based …
The FDA approved Nuplazid (pimavanserin) to treat hallucinations and delusions in people with Parkinson's disease psychosis. It is the first…
FDA May 2, 2026
FDA Approves Nuplazid (pimavanserin) for Parkinson's Disease Psychosis
Neurology FDA Approval
FDA Approves Nuplazid (pimavanserin) for Parkinson's Disease Psychosis FDA approves first drug for hallucinations in Parkinson's disease
FDA approved Nuplazid (pimavanserin) for hallucinations and delusions associated with Parkinson's disease psychosis. In a 6-week trial, Nupl…
The FDA approved Nuplazid (pimavanserin) to treat hallucinations and delusions in people with Parkinson's disease psychosis. It is the first…
FDA May 2, 2026